Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with Phase 2 clinical development of its lead candidate, Lucid-MS (Lucid-21-302), for the treatment of multiple sclerosis (MS). The FDA's approval of the Investigational New Drug (IND) application allows the company to initiate a randomized, double-blind, placebo-controlled study that will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with MS, using both clinical and radiological measures.
Lucid-MS is a first-in-class therapy designed to provide neuroprotection by inhibiting demyelination, the process by which the protective myelin sheath around nerve fibers is damaged. This mechanism differs from existing MS treatments, which primarily focus on modulating the immune system. The candidate targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. Preclinical models have shown that Lucid-MS can prevent and reverse myelin breakdown, offering a potential new approach to halting or even reversing disability progression in MS.
The company reports that Lucid-MS demonstrated a favorable safety profile and was well tolerated in Phase 1 trials involving healthy participants. With the IND now cleared, trial start-up activities, including site selection, are already underway. Patient enrollment and drug administration are expected to begin as quickly as possible, marking a significant step forward in the development of a potential new treatment for the millions of people worldwide affected by MS.
Quantum BioPharma is a biopharmaceutical company dedicated to developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has shown the ability to prevent and reverse myelin degradation in preclinical studies. The company also retains a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets an OTC version of its hangover remedy, and is entitled to royalty payments on sales of that product.
As of March 31, 2026, Quantum BioPharma reported having more than $10 million in cash, digital assets, and liquid investments, which will help fund the upcoming Phase 2 trial. This financial position, combined with the FDA's clearance, positions the company to advance its clinical program and potentially bring a new therapeutic option to MS patients who currently have limited treatment choices.
The advancement of Lucid-MS into Phase 2 is a notable development in the MS treatment landscape. If successful, it could offer a neuroprotective approach that addresses the underlying cause of disability rather than just managing symptoms. The trial's results will be closely watched by researchers, clinicians, and patients, as they could signal a shift in how MS is treated.
For more information on the full press release, visit https://ibn.fm/HyWYH. Updates on QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
